Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Consensus Rating of “Hold” by Analysts

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Twelve research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $20.25.

FUSN has been the subject of a number of research reports. William Blair cut Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Royal Bank of Canada restated a “sector perform” rating and set a $21.00 price target (up from $16.00) on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Jonestrading reiterated a “hold” rating on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Brookline Capital Management downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, Leerink Partnrs cut shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 19th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. increased its stake in shares of Fusion Pharmaceuticals by 1.9% in the 4th quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock valued at $104,616,000 after acquiring an additional 202,364 shares in the last quarter. Avidity Partners Management LP increased its position in Fusion Pharmaceuticals by 12.4% in the 4th quarter. Avidity Partners Management LP now owns 6,500,328 shares of the company’s stock valued at $62,468,000 after buying an additional 718,478 shares in the last quarter. FMR LLC boosted its holdings in Fusion Pharmaceuticals by 73.9% in the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after acquiring an additional 1,989,403 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Fusion Pharmaceuticals in the first quarter valued at approximately $10,405,000. Finally, Sphera Funds Management LTD. bought a new stake in shares of Fusion Pharmaceuticals during the first quarter valued at approximately $4,839,000. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Stock Performance

Fusion Pharmaceuticals stock opened at $21.31 on Monday. The company has a quick ratio of 15.01, a current ratio of 15.01 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.80 billion, a PE ratio of -14.50 and a beta of -0.72. Fusion Pharmaceuticals has a 12-month low of $2.31 and a 12-month high of $21.55. The business’s 50-day moving average price is $15.07 and its two-hundred day moving average price is $9.28.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. As a group, analysts expect that Fusion Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.